NCT04274140Active, not recruiting
Maternal Obesity and Offspring Neurodevelopment
Maternal Obesity and Offspring Neurodevelopment: the MOON Study
Source: ClinicalTrials.gov · Last updated 15 Dec 2025
Brief summary (registry, in English)
Our goals are to characterize the effects of maternal obesity during pregnancy on infant brain development, reveal the neurodevelopmental consequences, and identify possible mechanisms causing these effects. Our overall hypothesis is that maternal obesity during pregnancy exposes the fetus to an inflammatory environment that affects infant brain structural and functional development and consequently neurodevelopmental outcomes. To test this hypothesis, the investigators will recruit normal-weight and obese pregnant women, examine inflammatory markers associated with obese pregnancy, and correlate them with offspring's brain development evaluated using quantitative MRI methods and outcomes evaluated using neurodevelopmental tests.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 260 (estimated)
- First submitted
- 13 Nov 2019
- Start date
- 3 Oct 2019
- Primary completion date
- 30 Aug 2026
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Diseases
- Obesity
- NCT number
- NCT04274140
What you commit to
- Study type: Observational
- Planned participants: 260
- From 3 Oct 2019 to the primary completion date, 30 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- medications known to influence fetal growth
- recreational drugs, nicotine or tobacco (including smokeless) use or alcohol use while pregnant
Other illness
- hypertension, diabetes, or other preexisting medical conditions known or suspect (by the research team) to influence fetal growth;
- family history of psychological or neurogenetic disorders as determined by the research team that may increase the risk of adverse neurodevelopmental outcomes in offspring
- medical conditions developed during pregnancy (e.g. gestational diabetes, preeclampsia) known or suspected by the research team to influence fetal growth
Age
- infants born preterm (\<37 weeks of gestation), with congenital defects, intrauterine growth restriction, small for gestational age, macrosomia, hypoglycemia, low Apgar score (\<7), or any other medical complications at birth suspected affecting development
Other
- BMI measured at first study visit \<18.5 or between 26-29 or \>50
Who the study is looking for
- Singleton pregnancy
- 11-13 weeks of gestation -≥18 years of age.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Arkansas Children's Nutrition Center Coordinator of this site? Confirm its status | Little Rock | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.